Fondazione Instituto di Ricovero e Cura a Carattere Scientifico Cà Granda Ospedale Maggiore Policlinico, Endocrinology and Diabetology Unit, Via F. Sforza 35, 20122 Milan, Italy.
J Clin Endocrinol Metab. 2012 Nov;97(11):3983-8. doi: 10.1210/jc.2012-2477. Epub 2012 Aug 17.
Effects of GH replacement in patients with GH deficiency (GHD) after a cure for acromegaly so far have been poorly studied, although its prevalence among acromegalic patients may reach the 60%. The aim of the study was to evaluate whether metabolic parameters and quality of life are improved by GH replacement in patients with prior acromegaly and severe GHD.
This was a prospective study on 42 GHD subjects [22 men, mean age (sd): 48 ± 10]: 10 acromegalics treated with recombinant human GH (group A), 12 acromegalics who refused treatment (group B), and 20 subjects operated for nonfunctioning pituitary adenoma on recombinant human GH (group C). Serum IGF-I levels, lipid profile, glucose levels (fasting and after an oral glucose tolerance test), glycosylated hemoglobin, insulin resistance (homeostasis model assessment insulin resistance index), anthropometric parameters (body mass index, waist circumference, body composition), and quality of life (Questions on Life Satisfaction-Hypopituitarism Z-scores) were evaluated at baseline and after 12 and 36 months.
At baseline, group B showed higher IGF sd score than group A and C, as well as better quality of life and higher post-oral glucose tolerance test glucose levels than group A. After 12-months, similarly in group A and C, the IGF-I sd score significantly increased, and body composition and lipid profile improved, without deterioration of glucose tolerance. Quality of life significantly improved too, and the baseline difference between group A and B disappeared. Results were confirmed after 36 months.
In GHD acromegalic patients, GH therapy improved body composition, lipid profile, and quality of life as in patients with GHD due to nonfunctioning pituitary adenoma, without negative effects on glucose metabolism. GH replacement therapy should be considered in these patients, as in patients with GHD from other causes.
迄今为止,关于生长激素(GH)替代疗法对治愈肢端肥大症后生长激素缺乏(GHD)患者的影响研究甚少,尽管这类患者的发病率可能高达 60%。本研究旨在评估既往患有肢端肥大症且存在严重 GHD 的患者接受 GH 替代治疗后,代谢参数和生活质量是否得到改善。
这是一项前瞻性研究,共纳入 42 名 GHD 患者[22 名男性,平均年龄(标准差):48 ± 10]:10 名接受重组人生长激素(rhGH)治疗的肢端肥大症患者(A 组)、12 名拒绝治疗的肢端肥大症患者(B 组)和 20 名因无功能垂体腺瘤接受 rhGH 治疗的患者(C 组)。分别于基线时、12 个月和 36 个月时检测血清 IGF-I 水平、血脂谱、血糖(空腹和口服葡萄糖耐量试验后)、糖化血红蛋白、胰岛素抵抗(稳态模型评估的胰岛素抵抗指数)、人体测量参数(体重指数、腰围、身体成分)和生活质量(垂体功能减退症生活满意度问卷 Z 评分)。
基线时,B 组 IGF-I 的标准差评分高于 A 组和 C 组,且生活质量更好,口服葡萄糖耐量试验后血糖水平更高。12 个月时,A 组和 C 组 IGF-I 的标准差评分均显著升高,身体成分和血脂谱改善,糖耐量无恶化。生活质量也显著改善,且 A 组和 B 组之间的基线差异消失。36 个月时得到了类似的结果。
在 GHD 肢端肥大症患者中,GH 治疗可改善身体成分、血脂谱和生活质量,与因无功能垂体腺瘤所致 GHD 患者相似,对葡萄糖代谢无不良影响。此类患者应考虑接受 GH 替代治疗,就如同其他病因所致 GHD 患者一样。